300 related articles for article (PubMed ID: 16624886)
21. Proteasome-dependent pharmacological rescue of cystic fibrosis transmembrane conductance regulator revealed by mutation of glycine 622.
Norez C; Bilan F; Kitzis A; Mettey Y; Becq F
J Pharmacol Exp Ther; 2008 Apr; 325(1):89-99. PubMed ID: 18230692
[TBL] [Abstract][Full Text] [Related]
22. [Butyl-p-hydroxybenzoate stimulates cystic fibrosis transmembrane conductance regulator Cl- transport].
Ge H; Hou TT; Sun JJ; Yang H
Yao Xue Xue Bao; 2009 Jan; 44(1):32-7. PubMed ID: 19350818
[TBL] [Abstract][Full Text] [Related]
23. Topogenesis of cystic fibrosis transmembrane conductance regulator (CFTR): regulation by the amino terminal transmembrane sequences.
Chen M; Zhang JT
Biochemistry; 1999 Apr; 38(17):5471-7. PubMed ID: 10220334
[TBL] [Abstract][Full Text] [Related]
24. Sildenafil (Viagra) corrects DeltaF508-CFTR location in nasal epithelial cells from patients with cystic fibrosis.
Dormer RL; Harris CM; Clark Z; Pereira MM; Doull IJ; Norez C; Becq F; McPherson MA
Thorax; 2005 Jan; 60(1):55-9. PubMed ID: 15618584
[TBL] [Abstract][Full Text] [Related]
25. Molecular dissection of the butyrate action revealed the involvement of mitogen-activated protein kinase in cystic fibrosis transmembrane conductance regulator biogenesis.
Sugita M; Kongo H; Shiba Y
Mol Pharmacol; 2004 Nov; 66(5):1248-59. PubMed ID: 15304546
[TBL] [Abstract][Full Text] [Related]
26. Correctors enhance maturation of DeltaF508 CFTR by promoting interactions between the two halves of the molecule.
Loo TW; Bartlett MC; Clarke DM
Biochemistry; 2009 Oct; 48(41):9882-90. PubMed ID: 19761259
[TBL] [Abstract][Full Text] [Related]
27. Mild processing defect of porcine DeltaF508-CFTR suggests that DeltaF508 pigs may not develop cystic fibrosis disease.
Liu Y; Wang Y; Jiang Y; Zhu N; Liang H; Xu L; Feng X; Yang H; Ma T
Biochem Biophys Res Commun; 2008 Aug; 373(1):113-8. PubMed ID: 18555011
[TBL] [Abstract][Full Text] [Related]
28. Misassembled mutant DeltaF508 CFTR in the distal secretory pathway alters cellular lipid trafficking.
Gentzsch M; Choudhury A; Chang XB; Pagano RE; Riordan JR
J Cell Sci; 2007 Feb; 120(Pt 3):447-55. PubMed ID: 17213331
[TBL] [Abstract][Full Text] [Related]
29. Proinflammatory effect of sodium 4-phenylbutyrate in deltaF508-cystic fibrosis transmembrane conductance regulator lung epithelial cells: involvement of extracellular signal-regulated protein kinase 1/2 and c-Jun-NH2-terminal kinase signaling.
Roque T; Boncoeur E; Saint-Criq V; Bonvin E; Clement A; Tabary O; Jacquot J
J Pharmacol Exp Ther; 2008 Sep; 326(3):949-56. PubMed ID: 18574003
[TBL] [Abstract][Full Text] [Related]
30. Functional rescue of DeltaF508-CFTR by peptides designed to mimic sorting motifs.
Kim Chiaw P; Huan LJ; Gagnon S; Ly D; Sweezey N; Rotin D; Deber CM; Bear CE
Chem Biol; 2009 May; 16(5):520-30. PubMed ID: 19477416
[TBL] [Abstract][Full Text] [Related]
31. Trafficking of immature DeltaF508-CFTR to the plasma membrane and its detection by biotinylation.
Luo Y; McDonald K; Hanrahan JW
Biochem J; 2009 Apr; 419(1):211-9, 2 p following 219. PubMed ID: 19053947
[TBL] [Abstract][Full Text] [Related]
32. Modulation of deltaF508 cystic fibrosis transmembrane regulator trafficking and function with 4-phenylbutyrate and flavonoids.
Lim M; McKenzie K; Floyd AD; Kwon E; Zeitlin PL
Am J Respir Cell Mol Biol; 2004 Sep; 31(3):351-7. PubMed ID: 15191910
[TBL] [Abstract][Full Text] [Related]
33. S-nitrosylating agents: a novel class of compounds that increase cystic fibrosis transmembrane conductance regulator expression and maturation in epithelial cells.
Zaman K; Carraro S; Doherty J; Henderson EM; Lendermon E; Liu L; Verghese G; Zigler M; Ross M; Park E; Palmer LA; Doctor A; Stamler JS; Gaston B
Mol Pharmacol; 2006 Oct; 70(4):1435-42. PubMed ID: 16857740
[TBL] [Abstract][Full Text] [Related]
34. Is it go or NO go for S-nitrosylation modification-based therapies of cystic fibrosis transmembrane regulator trafficking?
Zeitlin PL
Mol Pharmacol; 2006 Oct; 70(4):1155-8. PubMed ID: 16877677
[TBL] [Abstract][Full Text] [Related]
35. Mutation specific therapy in CF.
Kerem E
Paediatr Respir Rev; 2006; 7 Suppl 1():S166-9. PubMed ID: 16798551
[TBL] [Abstract][Full Text] [Related]
36. Corrector VX-809 stabilizes the first transmembrane domain of CFTR.
Loo TW; Bartlett MC; Clarke DM
Biochem Pharmacol; 2013 Sep; 86(5):612-9. PubMed ID: 23835419
[TBL] [Abstract][Full Text] [Related]
37. The intact CFTR protein mediates ATPase rather than adenylate kinase activity.
Ramjeesingh M; Ugwu F; Stratford FL; Huan LJ; Li C; Bear CE
Biochem J; 2008 Jun; 412(2):315-21. PubMed ID: 18241200
[TBL] [Abstract][Full Text] [Related]
38. Cystic fibrosis transmembrane conductance regulator can export hyaluronan.
Schulz T; Schumacher U; Prante C; Sextro W; Prehm P
Pathobiology; 2010; 77(4):200-9. PubMed ID: 20616615
[TBL] [Abstract][Full Text] [Related]
39. Structural analog of sildenafil identified as a novel corrector of the F508del-CFTR trafficking defect.
Robert R; Carlile GW; Pavel C; Liu N; Anjos SM; Liao J; Luo Y; Zhang D; Thomas DY; Hanrahan JW
Mol Pharmacol; 2008 Feb; 73(2):478-89. PubMed ID: 17975008
[TBL] [Abstract][Full Text] [Related]
40. Misprocessing of the CFTR protein leads to mild cystic fibrosis phenotype.
Clain J; Lehmann-Che J; Duguépéroux I; Arous N; Girodon E; Legendre M; Goossens M; Edelman A; de Braekeleer M; Teulon J; Fanen P
Hum Mutat; 2005 Apr; 25(4):360-71. PubMed ID: 15776432
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
